Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Thymoma 1Thymic epithelial tumor 1Neoplasm, Residual 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 6pembrolizumab 5fludarabine phosphate 5Vinblastine 5Nivolumab 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Doxorubicin 5Dacarbazine 5fludarabine 4Whole-Body Irradiation 4Mycophenolic Acid 4Melphalan 4Magnetic Resonance Spectroscopy 4Brentuximab Vedotin 4pegfilgrastim 3Etoposide 3Cyclosporine 3Busulfan 3Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Fluorodeoxyglucose F18 2Azacitidine 2treosulfan 1tocilizumab 1thymoglobulin 1tafasitamab 1selinexor 1polatuzumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × AP 1903 reagent × 30 days × Clear all
NCT07164469 2026-06-05

Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡